ArticleScientific reports2025
Cerebral microstructural alterations as an imaging biomarker for Post-COVID-condition.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical utility and prospective of TMS-EEG: Updated review from an international expert group.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2026Review
- Longitudinal Monitoring of Brain Volume Changes After COVID-19 Infection Using Artificial Intelligence-Based MRI Volumetry.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop an imaging biomarker-based approach for the diagnosis of Post-COVID-condition (PCC) at the individual patient level. Magnetic resonance imaging (MRI) data from a prospective cohort of PCC patients (n = 89) were compared with a control group of unimpaired individuals who had contracted coronavirus disease 2019 (COVID-19) in the past (n = 38). Participants were divided into two groups: a training and a test cohort. The macrostructure, diffusion tensor imaging, and multi-shell-based microstructure imaging metrics were extracted using an atlas-based approach. These data were subsequently utilized to train a linear support vector machine (SVM). The efficacy of discrimination between the groups was evaluated for various combinations of input parameters. Upon comparison of the different input combinations, we found the highest area under the receiver operating characteristic curve (AUROC) for microstructural parameters. For the optimal combination of input parameters, an AUROC value of 0.95 with a sensitivity of 94% and a specificity of 85% was achieved, indicating high discriminatory potential but also underscoring the need for further validation given the non-negligible false-positive rate. The atlas regions with the highest discriminatory power include both gray (including multiple cortical areas, putamen and left thalamus) and white matter (including corpus callosum and frontal white matter). The use of a SVM allowed for the differentiation between PCC patients and UPC participants with high sensitivity using microstructural MRI data. While these findings mark a significant step toward a biomarker-based diagnosis of PCC, the moderate specificity and the monocentric design emphasize the need for confirmation in larger and multicentric cohorts before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.